American Board of Internal Medicine home page

Initial Certification indicates that physicians have met rigorous standards through intensive study, accredited training and evaluation and that they have the clinical judgment, skills and attitudes essential for the delivery of excellent patient care.

MOC is a professionally determined standard that attests that an internist is staying current in knowledge and practice throughout his/her career.

For more than 75 years, Certification by ABIM has stood for the highest standard in internal medicine and its 20 subspecialties.

Infectious Disease Board Exam Committee

Jan E. Patterson, MD, Chair

Dr. Patterson, who is board certified in Internal Medicine, Infectious Disease, Medical Quality and as a Healthcare CPD Professional, is Associate Dean for Quality & Lifelong Learning, Director of the Center for Patient Safety and Health Policy, and Professor of Medicine/Infectious Diseases and Pathology at The University of Texas Health Science Center at San Antonio. She is The University of Texas System Executive Vice Chancellor's Health Fellow in Clinical Effectiveness Programs and directs the Clinical Safety and Effectiveness course in San Antonio, a project-based quality improvement/patient safety curriculum for faculty and staff. The CME program she directs as Associate Dean achieved accreditation with commendation from the Accreditation Council for Continuing Medical Education in 2011.

Prior to going to San Antonio, Dr. Patterson was Assistant Professor of Medicine/Infectious Diseases at Yale School of Medicine. She also served as Associate Hospital Epidemiologist at Yale-New Haven Hospital and Hospital Epidemiologist at the VA Medical Center - West Haven.

Dr. Patterson has more than 20 years of experience and publications in the field of infection prevention, health care epidemiology and quality. She is currently Chair of the American Board of Internal Medicine Infectious Disease Board Exam Committee, having served on the committee since 2013. She is also a member of the Centers for Disease Control and Prevention's Healthcare Infection Control Practices Advisory Committee and is a past President of the Society for Healthcare Epidemiology of America. She has also served on the Board of Directors of the Infectious Diseases Society of America and the Commission for Certification of Healthcare CPD Professionals.

She received her medical degree from The University of Texas Medical School at Houston and is a distinguished alumna of that institution. She trained in internal medicine residency at Vanderbilt University Medical Center, and completed her infectious diseases fellowship at Yale School of Medicine. In 2010, she completed a master's degree in health care management at the Harvard T. H. Chan School of Public Health.

As of January 2017, Dr. Patterson reported the following external relationships:

Dr. Patterson serves on the Healthcare Infection Control Practices Advisory Committee of the U.S. Centers for Disease Control and Prevention, receiving reimbursement for travel expenses and a per diem for attending meetings.

  • Dr. Patterson is also a wholesale member of Young Living Essential Oils, as well as a consultant to Pfizer Independent Grants for Learning & Change (Medical Education).

David R. Andes, MD

Dr. Andes, a board certified infectious disease specialist, is a Professor in the Departments of Medicine, Medical Microbiology and Immunology, and Head of the Division of Infectious Disease at the University of Wisconsin, Madison. At the University of Wisconsin, Dr. Andes has served as a clinician scientist with a focus on drug-resistant infections. His research programs are multidisciplinary and strive to identify strategies to combat antimicrobial drug resistance. His study tactics span from the bench to the clinic, including defining the molecular basis for drug resistance, drug target development, pharmacodynamic investigation of novel anti-infectives and clinical trial study of resistance epidemiology.

Dr. Andes has published more than 230 papers, editorials, chapters and reviews, and 250 abstracts presented at national and international scientific meetings. He has been acknowledged for his research contributions in the area of infectious disease and drug resistance via the American Society for Microbiology Interscience Conference on Antimicrobial Agents and Chemotherapy Young Investigator Award.

Dr. Andes is a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee. He is past President of the International Society of Antimicrobial Pharmacology and was selected to the American Society of Clinical Investigation. He is Editor of Antimicrobial Agents and Chemotherapy and is on the editorial boards of numerous journals, including The Journal of Infectious Diseases, Infection and Immunity, and Infectious Disease. He has served as a member for NIH study sections annually since 2004. Dr. Beck co-authored the last two Infectious Diseases Society of America Candida Guidelines and participated in the CDC response to the multistate fungal meningitis outbreak in 2012. He also served as Director of the Infectious Diseases Fellowship Program from 2006 to 2014. Most recently, Dr. Andes served as the Director for Development of an National Institutes of Health Center of Excellence in Antimicrobial Drug Discovery and Development.

Dr. Andes received his medical degree from the University of Missouri School of Medicine. He completed a medicine residency at the University of Wisconsin, where he was selected Chief Resident. He subsequently undertook fellowship in infectious diseases at Wisconsin. Following fellowship, he pursued postdoctoral research training in pharmacology, drug resistance mechanisms and molecular mycology.

As of April 2017, Dr. Andes reported the following external relationships:

Pre-clinical research, with funding for clinical trial expenses and clinical research staff, paid directly to the University of Wisconsin, from the following companies:

  • Actelion Pharmaceuticals, for a study of a new antibiotic.
  • Paratek Pharmaceuticals, for a study of a new antibacterial agent.
  • Scynexis, for a study of a new antifungal agent.
  • Theravance, for a study of a new antibacterial agent.
  • Melinta Therapeutics, for a pharmacokinetic/pharmacodynamic study.
  • Iterum Therapeutics, for a pharmacokinetic/pharmacodynamic study.
  • Cidara Therapeutics, for a pharmacokinetic/pharmacodynamic study.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • Astellas Pharma, advising on pharmacokinetics and pharmacodynamics of isavuconazole a new antifungal, receiving reimbursement for travel expenses and honoraria.
  • Zavante, advising on pharmacokinetic/pharmacodynamic modeling, receiving reimbursement for travel expenses and honoraria.

Work as an author or editor for following company, with compensation as listed:

  • American Society for Microbiology, Editor, Antimicrobial Agents and Chemotherapy, receiving compensation as the editor and reimbursement for travel expenses.

Dr. Andes serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Infectious Diseases Society of America, Vice-Chair of Annual Program Committee, receiving reimbursement for travel expenses.

Helen W. Boucher, MD

Dr. Boucher, a board certified internist and infectious disease specialist, specializes in the care of immunocompromised patients, transplant-related infections, and S. aureus/MRSA infections. Her research focuses on antibiotic development and she advocates for increased development of medicines to treat antibiotic-resistant diseases. She is Director of the Infectious Diseases Fellowship Program, Director of the Ventricular Assist Device and Cardiac Transplant Infectious Diseases Program, and Staff Physician in the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center and Associate Professor of Medicine at Tufts University School of Medicine.

Dr. Boucher is a member of several professional organizations, among them the Infectious Diseases Society of America, the American Society for Microbiology, and the American Medical Association. In 1998, the Massachusetts Infectious Diseases Society awarded Dr. Boucher the Edward H. Kass Award for Clinical Excellence. In May 2006, she was elected to the Antimicrobial Availability Task Force (AATF, now the Antimicrobial Resistance Committee) of the Infectious Diseases Society of America (IDSA) and in October, 2007, she was elected to the Research Committee of the IDSA.

Dr. Boucher was elected a Fellow in the American College of Physicians in 2008. In 2009, she was appointed to the Steering Committee of the Mycoses Study Group. She has been included in Best Doctors in America since 2009. In 2011, Dr. Boucher was elected Fellow and Member of the Board of Directors of the Infectious Diseases Society of America. In 2012, she was elected to the American Board of Internal Medicine Infectious Disease Exam Writing Committee and in 2014, to the American Board of Internal Medicine Infectious Diseases Subspecialty Board.

In 2014 she was appointed Associate Editor of Antimicrobial Agents and Chemotherapy, to the Infectious Diseases Recruitment Task Force of the Infectious Diseases Society of America, and the ICAAC Program Committee. Dr. Boucher serves on the Board of Trustees of the Physicians of Tufts Medical Center and The College of the Holy Cross.

She received her medical degree from University of Texas Medical School at Houston and completed her training at Beth Israel Deaconess Medical Center.

As of January 2017, Dr. Boucher reported the following external relationships:

Service on data and safety monitoring boards for the following company, with compensation for honoraria:

  • Actelion Pharmaceuticals

Service on a research-related expert panel or advisory board for the following company, with compensation for travel expenses and honoraria:

  • Merck & Co.

Work as an author or editor for following company, with compensation as listed:

  • Elsevier, receiving compensation as an Editor.

Dr. Boucher serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Infectious Diseases Society of America, Board of Directors, Treasurer, receiving reimbursement for travel expenses.
  • College of the Holy Cross, Board of Trustees, receiving reimbursement for travel expenses.

Christina M. Coyle, MD

Dr. Coyle is Professor of Clinical Medicine, specializing in infectious diseases, at The Albert Einstein College of Medicine. In 2007, she became the Assistant Dean for Faculty Development. Dr. Coyle is board certified in Infectious Disease and has special expertise in parasitology. She is a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee.

Dr. Coyle is recognized as an expert in the larval tapeworms, Echinococcus, and in neurocysticercosis. She has co-authored chapters and articles on these and many other tropical diseases. She has run an active tropical medicine clinic in the United States since 2006. In 2007, she became a site director for GeoSentinel, the global surveillance network of the International Society of Travel Medicine and the Centers for Disease Control. She also functions in the Infectious Disease Society of America and American Society Tropical Medicine and Hygiene (ASTM&H) panel on guidelines for neurocysticercosis. In addition, she co-directs the annual ASTM&H Update Course since 2008, which provides clinically relevant education in the field of tropical medicine and parasitology, in order to reduce global health disparities.

Dr. Coyle is a deeply committed educator. Since her faculty appointment at Einstein in 1995, she has served in many different roles in medical education and has been the recipient of almost every teaching award at Einstein. In 2007, she was appointed Course Director of Parasitology and Global Medicine Course in the second-year medical student curriculum, the only free-standing tropical medicine course at a U.S. medical school. Dr. Coyle is a much-sought-after teacher and lectures frequently at other medical schools in New York City. As of 2010, she also lectures in the parasitology section of the microbiology course at Columbia Medical School in New York City.

Dr. Coyle is a graduate of Adelphi University and earned her medical degree at State University of New York-Downstate Medical Center. She completed her residency in internal medicine and a fellowship in infectious diseases at Bronx Municipal Hospital Center, and also holds a master of clinical research degree from Einstein.

As of January 2017, Dr. Coyle reported the following external relationships:

Dr. Coyle reported that she directs a course on recent advances in tropical medicine for the Society of Tropical Medicine and Hygiene.

Randall S. Edson, MD

Dr. Edson is currently the Internal Medicine Program Director at California Pacific Medical Center, San Francisco, California and also Clinical Professor of Medicine at the University of California San Francisco. He is board certified in both Internal Medicine and Infectious Disease.

Previously, Dr. Edson was Professor of Medicine at the Mayo Clinic College of Medicine, and had a 32-year career as an Infectious Diseases clinician and Internal Medicine Clinician/Educator. While at Mayo, Dr. Edson served as Program Director for the Infectious Diseases Fellowship Program and was a Senior Associate Program Director for the Internal Medicine Residency Program. In 2013, he was a recipient of the Distinguished Mayo Clinician award.

Dr. Edson currently serves on the Governor's Advisory Board for the Northern California Chapter of the American College of Physicians (ACP) and is Program Chair for the 2015 Annual Meeting of the All California Chapter of the ACP. Dr. Edson is a member of the American Board of Internal Medicine (ABIM) Infectious Disease Board Exam Committee. He previously served on the ABIM Internal Medicine Exam Committee. He was awarded mastership in the American College of Physicians in April 2013.

Dr. Edson received a bachelor's degree in music history at Yale College and a master's degree in music from the Yale School of Music. He attended medical school at the University of Iowa, and completed internal medicine residency and infectious diseases fellowship training at the Mayo School of Graduate Medical Education.

As of January 2017, Dr. Edson reported the following external relationships:

Dr. Edson serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Physicians, Program Chair for the California Chapter Meeting, without compensation.
  • American College of Physicians, Member of ACP Governor's Advisory Board, without compensation.

Kimberly Hanson, MD

Dr. Hanson is an Associate Professor of Medicine and Pathology. She is Director of the Transplant Infectious Diseases and Immunocompromised Host Service at the University of Utah and Section Head for Clinical Microbiology within ARUP Laboratories.

Previously, Dr. Hanson was a faculty member and Associate Director of the Molecular Microbiology Laboratory at Duke University Medical Center.

Dr. Hanson is board certified in both Infectious Disease and Medical Microbiology. She serves as a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee.

Dr. Hanson received her undergraduate and medical degrees from Northwestern University. She completed internal medicine training and was chief medical resident at Dartmouth-Hitchcock Medical Center. She then completed adult infectious diseases and medical microbiology fellowships at Duke, followed by a master’s degree in health sciences from the same institution.

As of January 2017, Dr. Hanson reported the following external relationships:

Service on research-related panel or advisory boards for the following companies, with compensation as listed:

  • Astellas, advising on the use and marketing messages for antifungal drugs, receiving honoraria.

Dr. Hanson serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Infectious Diseases Society of America, Diagnostics Policy Task Force member, without support.
  • Clinical Laboratory Standards Institute, Subcommittee on antifungal susceptibility testing, without support.
  • Infectious Diseases Society of America, Associate Editor, receiving consulting fees.

Howard M. Heller, MD

Dr. Heller is board certified in Internal Medicine and Infectious Disease. He is Associate Medical Director at the Massachusetts Institute of Technology (MIT), Associate Physician at Massachusetts General Hospital (MGH) in the infectious disease unit and Assistant Clinical Professor of Medicine, part-time, at Harvard Medical School.

At MIT, Dr. Heller practices primary care medicine and infectious disease and, as Associate Medical Director, is responsible for performance improvement, primary care, pediatrics, OB/GYN and mental health. He teaches in the Harvard-MIT Health Science and Technology (HST) program. At MGH, Dr. Heller serves on the infectious disease consult service, teaching and providing clinical care. He is a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee.

Dr. Heller has previously served as President of the Massachusetts Infectious Disease Society and is currently a member of the board. He previously served on several committees of the AIDS Clinical Trial Group of the National Institutes of Health and was co-investigator of several clinical trials.

Dr. Heller received a bachelor's degree in biology from Columbia College of Columbia University and his medical degree from SUNY-Upstate Medical University, (Syracuse). He trained in internal medicine at North Shore University Hospital/ Memorial Sloan Kettering Cancer Center (Cornell) and completed a fellowship in infectious diseases at SUNY-Stony Brook. He received a master's of public health degree from the Mailman School of Public Health of Columbia University. He is a Fellow of the Infectious Disease Society of America.

As of January 2017, Dr. Heller reported the following external relationships:

Work as an author or editor for following company, with compensation as listed:

  • UpToDate, receiving compensation for authorship.

Dr. Heller serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Massachusetts Infectious Disease Society, Board Member and Treasurer, without compensation.

Paul E. Sax, MD

Dr. Sax is Clinical Director of the Division of Infectious Diseases and the HIV Program at Brigham and Women's Hospital (BWH), and Professor of Medicine at Harvard Medical School. He is board certified in Internal Medicine and Infectious Diseases.

Dr. Sax is Editor-in-Chief of Open Forum Infectious Diseases, is on the Peer Review Board of the HIV/AIDS Section of UpToDate, and the Editorial Advisory Board of Medscape HIV/AIDS. Dr. Sax is also on the core faculty of the International AIDS Society - USA and the New England AIDS Education and Training Center. In addition to his clinical and teaching work, Dr. Sax's ongoing areas of research include clinical trials of antiretroviral therapies, cost-effectiveness of management strategies for HIV, and toxicity of antiretroviral therapy. He is presently the Principal Investigator at the BWH AIDS Clinical Trials Unit, and is a member of the Cost-Effectiveness of Preventing AIDS Complications Research Group. He serves as a member of the American Board of Internal Medicine Infectious Disease Board Exam Committee.

Dr. Sax received his medical degree from Harvard Medical School in 1987. He served his residency in internal medicine at BWH, while continuing his postdoctoral education with a fellowship in the Infectious Disease Unit of Massachusetts General Hospital.

As of January 2017, Dr. Sax reported the following external relationships.

Funding for clinical trial expenses and staff, paid to Brigham and Women's Hospital, from the following companies:

  • Bristol-Myers Squibb, to study atazanavir for endothelial dysfunction.
  • ViiV Healthcare, for a study of lamivudine and dolutegravir for HIV infection.

Service on a data and safety monitoring board for the following company, with compensation as listed:

  • Janssen Pharmaceuticals, for a study of darunavir plus cobicista-emtricitabine plus tenofovir alafenamide for treatment of HIV infection.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • AbbVie, to advise on treatments for hepatitis C infection, receiving reimbursement for travel expenses and honoraria.
  • Bristol-Myers Squibb, to advise on treatments for HIV infection, receiving reimbursement for travel expenses and honoraria.
  • Gilead, to advise on treatments for HIV and hepatitis C infection, receiving reimbursement for travel expenses and honoraria.
  • Merck & Co., to advise on treatments for HIV, hepatitis C and other infectious diseases, receiving reimbursement for travel expenses and honoraria.
  • ViiV Healthcare, to advise on treatments for HIV infection, receiving reimbursement for travel expenses and honorari.

Industry-supported continuing medical education supported by the following, with compensation as listed:

  • ViiV Healthcare, for HIV-related educational activities, receiving reimbursement for travel expenses and honoraria.
  • Janssen Pharmaceuticals, for HIV-related educational activities, receiving reimbursement for travel expenses and honoraria.

Work as an author or editor for following companies, with compensation as listed:

  • Infectious Diseases Society of America, receiving salary support for service as Editor-in-Chief of Open Forum Infectious Diseases.
  • UpToDate, receiving compensation as an author.